Your cells have an iron problem. Not a shortage one, but too much of the metal accumulating in the wrong places, triggering a chain reaction that ultimately kills the cell. Cancer researchers have spent years chasing this mechanism because it offers something chemotherapy struggles with: a way to kill cancer cells that bypasses the usual resistance pathways.
What is ferroptosis
Ferroptosis is a form of cell death that’s fundamentally different from apoptosis, the programmed death pathway we hear about constantly. Where apoptosis is like a controlled demolition with clear checkpoints and decision-making, ferroptosis is more like rust spreading uncontrollably through a machine.
At its core, ferroptosis happens when iron accumulates inside the cell and generates reactive oxygen species (ROS) through a chemical reaction called the Fenton reaction. These ROS are unstable molecules that attack the lipids in cell membranes. The cell’s normal antioxidant defence system, built around a protein called GPX4, usually neutralises these attacks. But when GPX4 gets blocked or depleted, the lipid damage accelerates past the point of no return. The cell membrane essentially falls apart from the inside.
The mitochondria sit at the centre of this chaos. These organelles store iron and control much of the cell’s metabolic activity. When ferroptosis kicks in, the mitochondria become the primary source of the ROS that destroys the cell from within.
What the research shows
Scientists have observed that cancer cells often develop resistance to traditional cell death pathways. They disable apoptosis. They ignore signals to stop growing. But ferroptosis uses a completely different route, which means cancer cells haven’t had evolutionary pressure to block it yet.
Studies demonstrate that targeting specific proteins can trigger ferroptosis in cancer cells while leaving healthy cells relatively unharmed. Researchers found that when they inhibit GPX4 in certain cancer models, the cells enter ferroptosis rapidly. The iron inside the mitochondria spins out of control, generating ROS that shreds the membrane lipids. Once the damage reaches a threshold, no repair mechanism can fix it.
What’s interesting is that some cancers are naturally more sensitive to ferroptosis than others. Certain leukaemias and some solid tumours show vulnerability to ferroptosis-inducing compounds in laboratory settings. Tumours with high iron content or abnormal iron metabolism appear particularly susceptible. This suggests that the cancer cells themselves have characteristics that make them dependent on iron metabolism in ways that healthy cells aren’t.
The mitochondrial component matters significantly here. Research shows that cancer cells with altered mitochondrial function respond differently to ferroptosis triggers. Some cancer cell types have mitochondrial defects that make them more reliant on iron-dependent metabolic pathways, which paradoxically creates an Achilles heel.
Why cells need this
Ferroptosis exists because cells need iron for survival, but too much of it becomes toxic. Iron is essential for making haemoglobin, for electron transport in mitochondria, for DNA synthesis. Nearly every metabolic process depends on it. But iron is also dangerous: a single free iron atom can generate ROS through the Fenton reaction.
Cells evolved GPX4 and other antioxidant systems to manage this razor-thin balance. They tightly regulate iron uptake, storage, and export. They sequester iron in proteins like ferritin to prevent it wandering around causing damage. Ferroptosis, in this view, is what happens when these regulatory systems fail catastrophically.
Cancer cells need even more iron than normal cells because they’re growing faster, dividing constantly, building new DNA and proteins. This increased demand creates metabolic stress around iron handling. The mitochondria in cancer cells often work differently too, sometimes becoming dependent on iron-requiring processes that normal cells can bypass. Evolution didn’t prepare these cells for death triggered through iron metabolism because that pathway was never meant to be weaponised.
What affects ferroptosis
Dietary iron intake influences how readily cells can undergo ferroptosis. Cells in iron-rich environments have more substrate for the Fenton reaction. Some research suggests that certain dietary patterns might affect cancer cell vulnerability to ferroptosis, though the evidence here is still preliminary and most studies occur in laboratory settings.
Age affects ferroptosis signalling. Older cells sometimes show altered iron metabolism and reduced antioxidant capacity, which could theoretically influence how responsive they are to ferroptosis triggers. Age-related changes in mitochondrial function also shift how cells handle iron.
Genetic background matters. Some cancer cells carry mutations that make them more or less dependent on GPX4. Certain genetic variants in iron metabolism genes affect how effectively ferroptosis can be induced. Drug interactions also influence the process; compounds that inhibit GPX4 work differently depending on what other medications or compounds are present.
Environmental factors like hypoxia (low oxygen) shift how cancer cells manage their iron and metabolic stress. Oxidative stress from any source makes cells more vulnerable to ferroptosis because their antioxidant systems become depleted faster.
What remains unknown
Researchers still don’t fully understand why some cancer types are sensitive to ferroptosis while others are resistant. The genetic and metabolic differences that determine sensitivity remain largely mysterious. We know ferroptosis happens, but predicting which patients’ cancers will respond to ferroptosis-based approaches remains guesswork.
The role of the tumour microenvironment in ferroptosis also needs clarification. Cancer cells don’t live in isolation; they’re surrounded by immune cells, fibroblasts, and other normal cells. How does ferroptosis in cancer cells affect this surrounding tissue? Does it trigger inflammation that helps or hinders treatment?
Questions remain about whether combining ferroptosis-inducing approaches with other treatments would improve outcomes, and if so, what combinations make sense. Scientists are still investigating whether cancer cells can develop resistance to ferroptosis, and if they can, how quickly that resistance emerges.
The mitochondrial dynamics during ferroptosis also deserve more attention. Which specific mitochondrial proteins control whether a cell lives or dies when iron triggers oxidative damage? Can we selectively target ferroptosis to cancer cell mitochondria while sparing those in healthy cells?
This area of cellular biology reveals something fundamental about how cancer cells are simultaneously more powerful and more fragile than normal cells. They’ve evolved to ignore many of the normal death signals, but in doing so they’ve become dependent on metabolic pathways that can be turned against them. Understanding ferroptosis points toward a broader truth: cancer cells’ survival strategies often contain the seeds of their destruction.
Matt Elliott is the editor of Redox News Today, an independent publication covering peer-reviewed research on cellular health, redox signalling, and related biomedical science.
